• The glycoprotein (GP) IIb/IIIa receptor inhibitors are even more effective in inhibiting platelet activation. (nih.gov)
  • In the era of potent P2Y 12 inhibitors, according to current guidelines, treatment with glycoprotein IIb/IIIa inhibitors (GPIs) should be limited to bail-out and/or highly thrombotic situations. (nih.gov)
  • However, not all patients in these trials received glycoprotein (GP) IIb/IIIa inhibitors. (acc.org)
  • Radial access was used in 71%, and glycoprotein IIb/IIIa inhibitors were used in fewer than 25% of patients who underwent percutaneous coronary intervention (PCI). (acc.org)
  • Bleeding was quite low, which may have been due to the high use of radial access and low use of glycoprotein IIb/IIIa inhibitors. (acc.org)
  • Low-molecular-weight heparins and platelet glycoprotein IIb/IIIa inhibitors have shown the potential to improve pharmacological reperfusion therapy. (nyu.edu)
  • Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: Initiate treatment early or wait for the catheterization laboratory? (mssm.edu)
  • Dive into the research topics of 'Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: Initiate treatment early or wait for the catheterization laboratory? (mssm.edu)
  • Vorchheimer, David A. / Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes : Initiate treatment early or wait for the catheterization laboratory? . (mssm.edu)
  • Objectives This study sought to evaluate the efficacy and safety of cangrelor compared with clopidogrel in subgroups that did and did not receive glycoprotein IIb/IIIa inhibitors (GPIs). (elsevierpure.com)
  • on behalf of the, CHAMPION Investigators & CHAMPION Investigators 2017, ' Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention ', Journal of the American College of Cardiology , vol. 69, no. 2, pp. 176-185. (elsevierpure.com)
  • Aspirin, glycoprotein (GP) IIb/IIIa inhibitors, and clopidogrel have an inhibitory effect on platelet activation and aggregation. (medscape.com)
  • Shear-Mediated Platelet Microparticles Demonstrate Phenotypic Heterogeneity as to Morphology, Receptor Distribution, and Hemostatic Function. (harvard.edu)
  • Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization. (harvard.edu)
  • Glanzmann thrombasthenia (GT) is a rare platelet disorder in which the platelets have qualitative or quantitative deficiencies of the fibrinogen receptor αIIbβ3. (medscape.com)
  • Background: In patients with ST-elevation myocardial infarction (STEMI), direct intracoronary bolus administration of the glycoprotein (GP) IIb/IIIa receptor antagonist abciximab is associated with a reduction in infarct size, better myocardial salvage, less microvascular obstruction and improved myocardial blush grade as compared to intravenous bolus injection, presumably caused by higher local drug concentrations leading to a more pronounced inhibition of platelet aggregation. (uni-luebeck.de)
  • We investigated whether there are differences in the degree of GP IIb/IIIa receptor occupancy and platelet inhibition in blood drawn from the coronary sinus (CS) shortly after intracoronary versus intravenous abciximab bolus administration. (uni-luebeck.de)
  • At late sampling after 30 min no significant differences were found between groups for both platelet reactivity and GP IIb/IIIa receptor occupancy. (uni-luebeck.de)
  • Conclusions: Acutely, direct intracoronary bolus injection resulted in a more pronounced local inhibition of platelet function and a higher degree of GP IIb/IIIa receptor occupancy as compared to standard intravenous bolus injection. (uni-luebeck.de)
  • Medications that inhibit the platelet glycoprotein IIb/IIIa receptor have been shown to be especially efficacious in the treatment of ACS. (mssm.edu)
  • Panel members preferred a single intravenous aspirin bolus or, in jurisdictions in which intravenous aspirin is not available, a glycoprotein IIb/IIIa receptor inhibitor as intraprocedural antiplatelet regimen and a combination therapy of oral aspirin and a P2Y12 inhibitor in the postprocedural period. (elsevierpure.com)
  • Panel members preferred intravenous aspirin or, alternatively, a glycoprotein IIb/IIIa receptor inhibitor as an intraprocedural antiplatelet agent, followed by a dual oral regimen of aspirin and a P2Y12 inhibitor in the postprocedural period. (elsevierpure.com)
  • Blockade of the platelet glycoprotein IIb/IIIa receptor by abciximab (c7E3 Fab) during coronary intervention reduces the incidence of ischemic complications, but has been associated with a doubling of the risk for bleeding complications. (houstonmethodist.org)
  • Selectively inhibits ADP binding to platelet receptor and subsequent ADP-mediated activation of glycoprotein GPIIb/IIIa complex, inhibiting platelet aggregation. (medscape.com)
  • The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. (itopmeds.com)
  • This active metabolite selectively inhibits adenosine diphosphate (ADP) binding to its platelet P2Y12 receptor and subsequently the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. (itopmeds.com)
  • The active metabolite of clopidogrel prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (itopmeds.com)
  • he drug specifically and irreversibly inhibits the P2Y12 subtype of ADP receptor, which is important in aggregation of platelets and cross-linking by the protein fibrin. (itopmeds.com)
  • No direct interference occurs with the GPIIb/IIIa receptor. (itopmeds.com)
  • As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. (itopmeds.com)
  • Qin R , Zhu H , Wang F , Song M , Lin P , Xing Y , Zhang W , Zhong M , Wang Z , . Platelet activation in diabetic mice models: the role of vascular endothelial cell-derived protein disulfide isomerase-mediated GP IIb/IIIa receptor activation. (aging-us.com)
  • GP IIb/IIIa receptor activation plays an important role in thrombosis. (aging-us.com)
  • It is a receptor for fibrinogen and von Willebrand factor and aids in platelet activation. (hemostasis.com)
  • The gpIIb/IIIa receptor is a target of several drugs including abciximab, eptifibatide, tirofiban. (hemostasis.com)
  • Platelet aggregation is stimulated by thromboxane and α2 receptor -activation, but inhibited by other inflammatory products like PGI2 and PGD2 . (wikidoc.org)
  • Results The A-allele of the rs12041331 SNP in the platelet endothelial aggregation receptor-1 ((rs12041331) reproducibly influenced platelet aggregation in aspirin-treated patients with coronary artery disease. (crispr-reagents.com)
  • The platelet surface hosts a panel of receptors mediating platelet activation and ultimately they all converge towards glycoprotein (GP) IIb/IIIa fibrinogen receptor complex. (crispr-reagents.com)
  • Los pequeños péptidos sintéticos que contienen la secuencia peptídica N-terminal no enmascarada pueden activar también el receptor en ausencia de actividad proteolítica. (bvsalud.org)
  • ITGA2B is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin and functions in platelet activation (5). (peertechzpublications.com)
  • Platelet membrane glycoprotein IIb-IIIa forms a calcium-dependent heterodimer and constitutes the fibrinogen receptor on stimulated platelets. (rupress.org)
  • 2001) A novel viper venom metalloproteinase, alborhagin, is an agonist at the platelet collagen receptor GPVI. (yoproteins.eu)
  • Platelet membrane glycoprotein complex important for platelet adhesion and aggregation. (harvard.edu)
  • 8. Khaspekova SG, Vyzova TV, Lukin VV, Tikhomirov OIu, Berndt M, Kouns W, Mazurov AV. (1996) [Conformational changes of the platelet membrane glycoprotein IIb-IIIa complex stimulated by a monoclonal antibody to the N-terminal segment of glycoprotein IIIa]. (yoproteins.eu)
  • 9. Khaspekova SG, Vlasik TN, Byzova TV, Vinogradov DV, Berndt MC, Mazurov AV. (1993) Detection of an epitope specific for the dissociated form of glycoprotein IIIa of platelet membrane glycoprotein IIb-IIIa complex and its expression on the surface of adherent platelets. (yoproteins.eu)
  • By blocking the amplification of platelet activation by released ADP, platelet aggregation induced by agonists other than ADP is also inhibited by the active metabolite of clopidogrel. (itopmeds.com)
  • Covalent binding to platelets has accounted for 2% of radiolabeled clopidogrel with a half-life of 11 days. (itopmeds.com)
  • Ticlopidine is a platelet aggregation inhibitor structurally and pharmacologically similar to clopidogrel. (lgmpharma.com)
  • Platelet activation by ADP (blocked by clopidogrel) leads to a conformational change in platelet gpIIb/IIIa receptors that induces binding to fibrinogen. (hemostasis.com)
  • 1. Khaspekova SG, Ziuriaev IT, Iakushkin VV, Golubeva NV, Ruda MIa, Mazurov AV. (2011) [Platelet aggregation upon acetylsalicylic acid and clopidogrel treatment and glycoprotein IIb/IIIa content in patients with acute coronary syndrome]. (yoproteins.eu)
  • The mechanism of early activation of GP IIb/IIIa receptors in diabetic conditions remains unknown. (aging-us.com)
  • In conclusion, EMP-PDI promotes early platelet activation through glycoprotein (GP) IIb/IIIa receptors present on platelet surface in the diabetic state. (aging-us.com)
  • However, the ultimate common pathway of platelet aggregation is the activation of glycoprotein (GP) IIb/IIIa receptors present on platelet surface [ 7 - 9 ]. (aging-us.com)
  • Under physiological conditions, the GP IIb/IIIa receptors are present in a low-affinity state and cannot bind to fibrinogen. (aging-us.com)
  • This process relies on the destruction of disulfide bonds present on these receptors, such as Cys5-Cys435, Cys663-Cys687, and a third Cys-rich repetitive zone, to be transformed into the ligand-binding, high-affinity state and evoke conformational changes in GP IIb/IIIa receptors [ 10 ]. (aging-us.com)
  • BACKGROUND: Studies have been performed on human fresh, liquid-preserved, and cryopreserved platelets (PLTs) to assess PLT-adhesive surface receptors, PLT membrane procoagulant activity, PLT aggregation, and thromboxane production. (umassmed.edu)
  • Platelets are activated when brought into contact with collagen (which is exposed when the endothelial blood vessel lining is damaged), thrombin (primarily through PAR -1), ADP receptors (P2Y1 and P2Y12) expressed on platelets, a negatively charged surface (e.g. glass), or several other activating factors. (wikidoc.org)
  • The platelets adhere to each other via adhesion receptors or integrins , and to the endothelial cells in the wall of the blood vessel forming a haemostatic plug in conjunction with fibrin . (wikidoc.org)
  • Other receptors include GPIb-V-IX complex (vWF) and GPVI ( collagen ). (wikidoc.org)
  • However given the considerable interdependency of platelet activation pathways and the fact that aspirin has effects impartial of COX-1 [8]-[9] the effect of aspirin may also be susceptible to genetically decided changes of various other receptors. (crispr-reagents.com)
  • The A to Z trial is the first large, randomized trial to examine the safety and efficacy of the combination of enoxaparin versus UFH with use of a GP IIb/IIIa inhibitor. (acc.org)
  • Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. (duke.edu)
  • Dipyridamole is a platelet adhesion inhibitor that possibly inhibits RBC uptake of adenosine, itself an inhibitor of platelet reactivity. (medscape.com)
  • It has been proposed that 1 or more active metabolites may account for ticlopidine's activity, because ticlopidine itself is an extremely weak platelet aggregation inhibitor in vitro at the concentrations achieved in vivo. (lgmpharma.com)
  • Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher Disease. (harvard.edu)
  • Flow cytometry can be used to measure platelet reactivity, circulating activated platelets, platelet-platelet aggregates, leukocyte-platelet aggregates, procoagulant platelet-derived microparticles, and calcium flux. (umassmed.edu)
  • Furthermore heritable factors take into account around 30% from the variant in innate platelet reactivity [5] and Hydroxocobalamin (Vitamin B12a) hereditary variability can be an essential contributor to residual platelet reactivity during aspirin treatment [6]. (crispr-reagents.com)
  • Dematin Regulates Calcium Mobilization, Thrombosis, and Early Akt Activation in Platelets. (harvard.edu)
  • Exploratory Use of Glycoprotein IIb/IIIa Inhibition in Prevention of Blalock-Taussig Shunt Thrombosis. (harvard.edu)
  • The main effectors of coronary thrombosis are platelets, and hence, alterations of platelets and their functional characteristics may represent a conceptual bridge between these events. (johnshopkins.edu)
  • May be used in low dose to inhibit platelet aggregation and improve complications of venous stasis and thrombosis. (medscape.com)
  • In thrombosis, platelet activation serves as the initiation factor. (aging-us.com)
  • Dysfunction or low levels of platelets predisposes to bleeding , while high levels, although usually asymptomatic, may increase the risk of thrombosis . (wikidoc.org)
  • Both hemostasis and thrombosis depend on the coagulation cascade, vascular wall integrity, and platelet response. (medscape.com)
  • Here the current status of our knowledge is reviewed with specific emphasis upon the role of the platelet in the pathogenesis of thrombosis as well as the impact of recent data from ECLAP and MRC PT1. (ashpublications.org)
  • Thrombosis predominates in ET and PV and these entities are the subject of this article focussing upon the nature of thrombotic events and their pathogenesis, with an emphasis upon platelets. (ashpublications.org)
  • Integrin alpha 2b (ITGA2b), also known as CD41 and GPIIb, is a transmembrane glycoprotein that is expressed by megakaryocytes and platelets. (rndsystems.com)
  • CD41/CD61 is expressed on platelets and megakaryocytes, and plays a role in platelet activation and aggregation through interaction with fibrinogen, fibronectin, vWF, and other RGD-containing adhesion molecules. (biolegend.com)
  • Platelets are produced in hematopoiesis by budding off from megakaryocytes . (wikidoc.org)
  • Biosynthesis and processing of platelet GPIIb-IIIa in human megakaryocytes. (rupress.org)
  • To examine the biosynthesis and processing of GPIIb-IIIa, purified human megakaryocytes were isolated from liquid cultures of cryopreserved leukocytes stem cell concentrates from patients with chronic myelogenous leukemia. (rupress.org)
  • The glycosylation of GPIIb-IIIa was examined in megakaryocytes by metabolic labeling in the presence of tunicamycin, monensin, or treatment with endoglycosidase H. The polypeptide backbones of the GPIIb and the GPIIIa have molecular masses of 120 and 90 kD, respectively. (rupress.org)
  • The antibody reacts with human platelets and megakaryocytes. (yoproteins.eu)
  • The platelet integrin αIIbβ3, also known as the glycoprotein GPIIb/IIIa (CD41/CD61) complex, is essential for normal platelet function. (medscape.com)
  • Most patients have a normal platelet size and count. (medscape.com)
  • The complex is formed via calcium-dependent association of gpIIb and gpIIIa, a required step in normal platelet aggregation and endothelial adherence. (hemostasis.com)
  • A normal platelet count in a healthy person is between 150,000 and 400,000 per mm³ of blood (150-400 x 10 9 / L ). 95% of healthy people will have platelet counts in this range. (wikidoc.org)
  • Glycoprotein IIb/IIIa (GPIIb/IIIa, also known as integrin αIIbβ3) is an integrin complex found on platelets. (hemostasis.com)
  • CD61, also known as integrin ß3 and glycoprotein IIIa (gpIIIa), is a 90 kD type I integral transmembrane glycoprotein. (biolegend.com)
  • Detection of Integrin alpha 2b/CD41 in Human Blood Platelets by Flow Cytometry. (rndsystems.com)
  • Human peripheral blood platelets were stained with FITC-conjugated Anti-Human Integrin a2b/CD41 Antibody (Clone P2) and either (A) Mouse Anti-Human Integrin a2b/CD41 APC-conjugated Monoclonal Antibody (Catalog # FAB7616A) or (B) Mouse IgG 1 Allophycocyanin Isotype Control (Catalog # IC002A ). (rndsystems.com)
  • It is a member of the integrin family, associating with platelet gpIIb (CD41) to form CD41/CD61 complex and with integrin aV (CD51) to form aV/ß3 (CD51/CD61) integrin. (biolegend.com)
  • The purpose of this study was to investigate the release of Endothelial microparticle (EMP)-associated protein disulfide isomerase (PDI) after endothelial cell injury induced in diabetes and the changes in platelet activation. (aging-us.com)
  • The exact biological mechanism remains elusive but the effect of this polymorphism may be related to changes in platelet activation. (crispr-reagents.com)
  • May have positive influence on several hemorrhagic parameters and may exert protection against atherosclerosis (inhibition of platelet function and changes in hemorrhagic profile). (medscape.com)
  • Reduction and weight adjustment of heparin dose and early sheath removal in the setting of platelet inhibition with abciximab during coronary intervention may be useful in diminishing the incidence of hemorrhagic complications without loss of clinical efficacy. (houstonmethodist.org)
  • Recombinant coagulation factor VIIa is approved for bleeding episodes and perioperative management in patients with GT refractory to platelet transfusions, with or without antibodies to platelets. (medscape.com)
  • Integrin alpha 2b is required for platelet aggregation, and defects lead to disorders of coagulation. (rndsystems.com)
  • This inhibits platelet aggregation and coagulation. (neisslabs.com)
  • Once activated, they release a number of different coagulation factors and platelet activating factors. (wikidoc.org)
  • Flow cytometry can also be used in the following clinical settings: monitoring of GPIIb-IIIa antagonist therapy, diagnosis of inherited deficiencies of platelet surface glycoproteins, diagnosis of storage pool disease, diagnosis of heparin-induced thrombocytopenia, and measurement of the rate of thrombopoiesis. (umassmed.edu)
  • Scholars@Duke publication: Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. (duke.edu)
  • Moreover, even marginal clinical benefits, together with recently reported severe bleeding events in some patients receiving oral platelet glycoprotein IIb/IIIa therapy, may potentially advance sertraline as a safe and efficient adjunct to the current therapeutic approach to the acute coronary syndrome. (johnshopkins.edu)
  • Clinical applications of whole blood flow cytometric assays of platelet function in disease states (e.g., acute coronary syndromes, angioplasty, and stroke) may include identification of patients who would benefit from additional antiplatelet therapy and prediction of ischemic events. (umassmed.edu)
  • Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? (edu.pl)
  • 2010) [Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation]. (yoproteins.eu)
  • Koray Ak, Ergun S, Altınoz H, Uyguner ZO, Tetik S (2016) GG Polymorphism of Platelet ITGA2B Gene Increases the Magnitude of Interleukin-6 Release after Cardiopulmonary Bypass. (peertechzpublications.com)
  • In this study we aimed to investigate the effect of ITGA2B (integrin alpha 2b, platelet glycoprotein IIb of IIb/IIIa complex) gene polymorphism on the magnitude of inflammatory response after CPB. (peertechzpublications.com)
  • 3. Sirotkina OV, Khaspekova SG, Zabotina AM, Shimanova YV, Mazurov AV. (2007) Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists. (yoproteins.eu)
  • However, diabetic patients have significantly higher platelet aggregation and activation than non-diabetic patients, including those undergoing dual antiplatelet therapy [ 4 - 6 ]. (aging-us.com)
  • Inhibits prostaglandin synthesis, which prevents formation of platelet-aggregating thromboxane A2. (medscape.com)
  • May also inhibit phosphodiesterase activity, leading to increased cyclic-3', 5'-adenosine monophosphate levels in platelets and formation of the potent platelet activator thromboxane A2. (medscape.com)
  • STUDY DESIGN AND METHODS: In both human and baboon fresh and lyophilized PLTs, aggregation response and PLT production of thromboxane A2 were measured after stimulation, and PLT surface markers P-selectin, glycoprotein (GP) Ib, GPIIb-IIIa, and factor (F) V were measured before and after stimulation. (umassmed.edu)
  • RESULTS: Fresh PLTs responded to the dual agonists arachidonic acid and adenosine diphosphate (ADP) to aggregate and produce thromboxane A2, and in both the PLT surface markers P-selectin and GPIIb-IIIa increased and GPIb decreased after stimulation. (umassmed.edu)
  • There was no consensus on the role of platelet function testing in the postprocedural period. (elsevierpure.com)
  • M, Gresele P. Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. (umassmed.edu)
  • Mumford AD, Frelinger AL, Gachet C, Gresele P, Noris P, Harrison P, Mezzano D. A review of platelet secretion assays for the diagnosis of inherited platelet secretion disorders. (umassmed.edu)
  • The antibody is specific to the integrin complex alpha 2b beta 3, but not to the dissociated integrins. (yoproteins.eu)
  • It is an integrin complex containing INTEGRIN ALPHAIIB and INTEGRIN BETA3 which recognizes the arginine-glycine-aspartic acid (RGD) sequence present on several adhesive proteins. (harvard.edu)
  • The antibody does not react with platelets from patients with the hereditary deficiency of GP IIb-IIIa (Glanzmann's thrombasthenia). (yoproteins.eu)
  • The collagen-induced platelet aggregation of platelet-rich plasma samples from 14 healthy rabbits was measured turbidometrically using a platelet aggregometer, before and 1 hour after intravenous injection of alum. (who.int)
  • Collagen-induced platelet aggregation was significantly reduced after alum injection. (who.int)
  • contradiction in the mechanism of action of alum, we evaluated the in vivo effect of Alum (aluminium potassium sulfate) is a alum in terms of collagen-induced platelet food additive and traditional remedy used to aggregation and bleeding time. (who.int)
  • These drugs provide not only a safe blockade of serotonin reuptake in the brain, but also in platelets, thus potentially protecting them from activation. (johnshopkins.edu)
  • They are found primarily on PLATELETS and on ENDOTHELIAL CELLS. (bvsalud.org)
  • Methods This pooled, patient-level analysis of the 3 CHAMPION (Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) trials analyzed all randomized patients who underwent PCI and received the study drug (n = 24,902). (elsevierpure.com)
  • A defect in either glycoprotein can lead to a bleeding disorder. (medscape.com)
  • Platelets , or thrombocytes , are the cells circulating in the blood that are involved in the cellular mechanisms of primary hemostasis leading to the formation of blood clots . (wikidoc.org)
  • Platelets are small cells that circulate in blood and are an essential component of blood clots. (medlineplus.gov)
  • Platelets stored in plasma or in GAC were equally functional when tested for aggregation and adenosine triphosphate (ATP) secretion. (amsterdamumc.org)
  • Activation of platelets was measured by binding of monoclonal antibodies (McAb) against the Gp IIb/IIIa complex and against activation‐dependent antigens (GMP 140 from the α‐granules and a 53‐kD glycoprotein from the lysosomal granules). (amsterdamumc.org)
  • 2001) [Inhibition of thrombocyte aggregation by F(ab')2-fragments of monoclonal antibodies FraMon (CRC64) to glycoproteins IIb-IIIa]. (yoproteins.eu)
  • Patients with GT who are bleeding require platelet transfusion. (medscape.com)
  • Patients with Glanzmann thrombasthenia can have severe bleeding problems, but their prognosis remains good with appropriate supportive care and platelet transfusions if necessary. (medscape.com)
  • Nevertheless, the platelet-related properties of SSRI may strongly affect the incidence of complications in patients with ischemic heart disease. (johnshopkins.edu)
  • Angioembolization with added infusion of factor VII, can be considered an equally effective alternate to platelet transfusion in patients of GT, who present with recurrent bleeding. (aeirc-edu.com)
  • Ces résultats semblent indiquer que l'utilisation de l'alun en tant qu'antiplaquettaire oral pourrait faire l'objet d'études complémentaires, en tenant compte des effets secondaires éventuels notamment chez les patients dont la fonction rénale est altérée. (who.int)
  • It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. (itopmeds.com)
  • The contents of the granules are released upon activation of the platelet. (wikidoc.org)
  • Immunoprecipitation of [35S]methionine pulse-chase-labeled cell extracts by antibodies specific for the alpha or beta subunits of GPIIb indicated that GPIIb was derived from a precursor of Mr 130,000 that contains the alpha and beta subunits. (rupress.org)
  • We conclude that platelets prepared by the buffy‐coat method and stored in GAC have the same in vitro qualitities as platelets stored in plasma, except for the lower aggregation response by the archidonic‐acid pathway. (amsterdamumc.org)